Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis Growth Continues with Big Money Boosts
07:09am, Wednesday, 19'th Mar 2025
Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
12:10pm, Tuesday, 25'th Feb 2025
Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.
EXEL or TECH: Which Is the Better Value Stock Right Now?
12:45pm, Monday, 24'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investo
Why Exelixis Stock Trounced the Market on Thursday
06:31pm, Friday, 21'st Feb 2025
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
01:30pm, Friday, 21'st Feb 2025
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
05:05pm, Thursday, 20'th Feb 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Thursday, 20'th Feb 2025
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
10:16am, Tuesday, 18'th Feb 2025
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
International Markets and Exelixis (EXEL): A Deep Dive for Investors
10:16am, Monday, 17'th Feb 2025
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Op
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Friday, 14'th Feb 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
02:51pm, Wednesday, 12'th Feb 2025
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
09:04am, Wednesday, 12'th Feb 2025
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
08:24pm, Tuesday, 11'th Feb 2025
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morr
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Tuesday, 11'th Feb 2025
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa
